Evotec SE has announced that it is expected to receive approximately $100 million in upfront consideration upon closing of the sale of Tubulis GmbH to Gilead Sciences.
Evotec is eligible to receive up to approximately $58 million in additional contingent consideration in line with its equity participation and subject to the achievement of specified milestones.
Closing of the transaction is expected in the second quarter of 2026, subject to customary closing conditions. Further details of the transaction were announced today by Gilead Sciences and Tubulis.
Through its Evotec Ventures activities, Evotec holds a 3.14% equity stake in Tubulis. The company was an investor in Tubulis’ €60 million Series B financing round in May 2022, as well as a €128 million Series B2 round which closed in March 2024. Tubulis currently has two programs in clinical trials for high-need solid tumour indications.
The transaction represents the fourth successful monetisation of assets from Evotec’s investment portfolio, reflecting the company’s disciplined approach to value realization.
Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: ‘This transaction marks an important milestone for Tubulis and its continued clinical progress. We are pleased to have supported the company in its development and wish the team continued success as it advances its clinical programmes.
‘Through our own work in antibody-drug conjugate discovery and development, we recognise the incredible potential that this modality possesses in delivering potentially superior cancer therapeutics.’
